MBP-Tracker Platform

MBP-Tracker Platform

 

Aquila’s MBP-Tracker screening platform incorporates sophisticated in vitro and ex vivo analysis, enablingw detailed interrogation of the fate of antigen-reactive, pathogenic T cells, from simple expression of cell surface molecules, to immune-purification, allowing downstream transcriptome analysis. In vitro assays can be used to screen larger numbers of compounds before progressing to in vivo T cell priming studies or MBP-Tracker EAE, which allows specific assessment of traceable, antigen-reactive cells ex vivo.

Stage 1. In Vitro
In vitro MBP-reactive T cell assays offer a time efficient screen to determine on-target compound effects following antigen specific-TCR stimulation. The use of MBP-reactive splenocytes in vitro has the benefit of physiologically relevant TCR stimulation by MBP peptide antigen, to more accurately model in vivo activation of pathogenic T cells and the ability of compound to affect phenotype/effector function.
Compound effects can be assessed prophylactically or therapeutically upon re-stimulation of activated splenocytes:

  • Cytokine production by ELISA/multiplex array (eg. IFN-γ, IL 17, IL-10 and more)
  • Flow cytometry (cytokines, transcription factors, activation markers, proliferation, viability)
  • Cytotoxicity assays (LDH)

Stage 2. In Vivo Priming
In vivo priming of MBP-Tracker cells is used to determine on-target compound effects in short, cost-effective in vivo studies. Ex vivo analysis of primed MBP-Tracker cells in response to compound can be determined by:

  • Splenic recall assays to assess proliferative capacity and cytokine production by ELISA/multiplex array (e.g. IFN-γ, IL 17, IL-10 and more)
  • Flow cytometry (cytokines, transcription factors, activation markers, proliferation, viability)

Stage 3. In Vivo MBP-Tracker EAE
Our unique EAE model allows us to obtain clinical efficacy and mode of action data from individuals treated prophylactically or therapeutically with compounds. Pathogenic MBP-Tracker cells can be isolated from both peripheral lymphoid organs and CNS to elucidate compound mode of action by:

  • Splenic recall assays to assess proliferative capacity and cytokine production by ELISA/multiplex array (eg. IFN-γ, IL 17, IL-10 and many more)
  • Flow cytometry (cytokines, transcription factors, activation markers, proliferation, viability)

CONTACT US

We’d be happy to discuss any service or product you may be interested in.

Aquila BioMedical Ltd.
Nine, Edinburgh BioQuarter
9, Little France Road
Edinburgh
EH16 4UX
UK

Tel: +44 (0) 131 658 5164
Email: info@aquila-bm.com

SEND MESSAGE